c-erbB2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases

Journal of Clinical Oncology

Volumn 14, Issue 10, 1996, Pages 2702-2708

  Carlomagno, C ^a   Perrone, F ^a   Gallo, C ^a   De Laurentiis, M ^a   Lauria, R ^a   Morabito, A ^a   Pettinato, G ^a   Panico, L ^a   D'Antonio, A ^a   Bianco, A R ^a   De Placido, S ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; ONCOGENE C ERB; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; AXILLA; BREAST TUMOR; FEMALE; FOLLOW UP; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; AXILLA; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM PROTEINS; RECEPTOR, ERBB-2; TAMOXIFEN;

EID: 0029662337     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.10.2702     Document Type: Article

References (37)

1. Holmes W, Sliwkoski MX, Akita RW, et al: Identification of heregulin, a specific activator of p185-erbB2. Science 256:1205-1210, 1992
2. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987
3. Slamon JS, Godolphin W, Jones LA, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712, 1989
4. Toikkenen S, Helin H, Isola J, et al: Prognostic significance of HER-2 oncoprotein expression in breast cancer: A 30-year follow up. J Clin Oncol 10:1044-1048, 1992
5. Gusterson BA, Gelber RD, Goldhirsch A, et al: Prognostic importance of c-erbB2 expression in breast cancer. J Clin Oncol 10:1049-1056, 1992
6. Hartmann LC, Ingle JN, Wolr LE, et al: Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer. Cancer 74:2956-2963, 1994
7. Tetu B, Brisson J: Prognostic significance of the pattern of immunostaining and adjuvant therapy. Cancer 73:2358-2365, 1994
8. Borg A, Baldetorp B, Ferno M, et al: ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett 81:137-144, 1994
9. Allred DC, Clark GM, Tandon AK, et al: HER-2/neu in node-negative breast cancer: Prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 10:599-605, 1992
10. Paik S, Hazan R, Fisher ER, et al: Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: Prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 8:103-112, 1990
11. Paterson MC, Dietrich KD, Danyluc J. et al: Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer. Cancer Res 51:556-567, 1991
12. Lovekin C, Ellis IO, Locker A, et al: c-erbB2 oncoprotein expression in primary and advanced breast cancer. Br J Cancer 63:439-443, 1991
13. Klijn JGM, Berns EMJJ, Bontenbal M, et al: Cell biological factors associated with the response of breast cancer to systemic treatment. Cancer Treat Rev 19:45-63, 1993
14. Wright C, Nicholson S, Angus B, et al: Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 65:118-121, 1992
15. Bianco AR, De Placido S, Gallo C, et al: Adjuvant therapy with tamoxifen in operable breast cancer. 10 year results of the Naples (GUN) Study. Lancet 2:1095-1099, 1988
16. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339:1-15, 71-85, 1992
17. Bloom HJG, Richardson WW: Histological grading and prognosis in breast cancer. A study of 1409 cases of which 539 have been followed for 15 years. Br J Cancer 11:359-377, 1957
18. LeDoussal V, Tubiana-Hulin M, Friedman S, et al: Prognostic value of histologic nuclear grade components of Scarff-Bloom-Rich-ardson (SBR). Cancer 64:1914-1921, 1989
19. McGuire WL, De La Garza M, Chamness GC: Evaluation of estrogen receptors assays in human breast cancer tissue. Cancer Res 37:637-639, 1977
20. Cox DR: Regression models and life table. J R Stat Soc (B) 34:187-220, 1972
21. Kaplan EL, Meier P: Non parametric estimation from incomplete observation. J Am Stat Assoc 53:457-481, 1958
22. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
23. Winstanley J, Cooke T, Murray GD, et al: The long term prognostic significance of c-erbB2 in primary breast cancer. Br J Cancer 63:447-450, 1991
24. Gullik WJ, Love SB, Wright C, et al: c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer 63:434-438, 1991
25. Muss HB, Thor AD, Berry DA, et al: c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330:1260-1266, 1994
26. Cobleigh MA, Bines J, Harris D, et al: Amenorrhea following adjuvant chemotherapy for breast cancer. Proc Am Soc Clin Oncol 14:115, 1995 (abstr 158)
27. Leitzel K, Teramoto Y, Konrad K, et al: Elevated serum c-erbB2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 13:1129-1135, 1995
28. Benz CC, Scott GK, Sarup JC, et al: Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 24:85-95, 1992
29. Liu Y, El-Ashry D, Chen D, et al: MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo. Breast Cancer Res Treat 34:97-117, 1995
30. Pietras RJ, Arboleda J, Reese DM, et al: HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10:2435-2446, 1995
31. Berger MS, Locher GW, Sauer S, et al: Correlation of erbB2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res 48:1238-1243, 1988
32. O'Reilly SM, Barnes DM, Camplejohn RS, et al: The rela tionship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer. Br J Cancer 63:444-446, 1991
33. Read LD, Keith D, Slamon DJ, et al: Hormonal modulation of HER-2/neu protooncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines. Cancer Res 50:3947-3951, 1990
34. Baselga J, Tripathy D, Mendelsonn J, et al: Ongoing phase II study of intravenous recombinant human anti-p185 HER 2 monoclonal antibody 4D5 (MAb 4D5) in patients with stage IV breast cancer overexpressing HER2. Breast Cancer Res Treat 32:30, 1994 (suppl, abstr 8)
35. Pegram M, Lipton A, Pietras R, et al: Phase II study of intravenous recombinant humanized anti-p185 HER-2 monoclonal antibody (rhuMAb HER-2) plus cisplatin in patients with HER-2/ NEU overexpressing metastatic breast cancer. Proc Am Soc Clin Oncol 14:106, 1995 (abstr 124)
36. Pietras Rj, Fendly BM, Chazin VR, et al: Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 9:1829-1838, 1994
37. Lin RJ, Brink J, Xuan JA, et al: An antibody directed against the c-erbB2 protein enhances the inhibitory activity of tamoxifen against estrogen-dependent c-erbB2 expressing breast tumor cell lines. Breast Cancer Res Treat 32:31, 1994 (suppl, abstr 9)